DK2831117T3 - ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF - Google Patents

Info

Publication number

DK2831117T3

DK2831117T3 DK13715871.3T DK13715871T DK2831117T3 DK 2831117 T3 DK2831117 T3 DK 2831117T3 DK 13715871 T DK13715871 T DK 13715871T DK 2831117 T3 DK2831117 T3 DK 2831117T3

Authority

DK

Denmark

Prior art keywords

seq

amino acid

acid sequence

antibody

tlr4

Prior art date

2012-03-29

Links

• Espacenet
• Global Dossier
• Discuss

• 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims description 198
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 198
• 150000001413 amino acids Chemical group 0.000 claims description 185
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 60
• 102000045717 human TLR4 Human genes 0.000 claims description 60
• 238000006467 substitution reaction Methods 0.000 claims description 23
• 238000011282 treatment Methods 0.000 claims description 18
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 14
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 14
• 210000004369 blood Anatomy 0.000 claims description 10
• 239000008280 blood Substances 0.000 claims description 10
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• 230000000903 blocking effect Effects 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 5
• 230000017306 interleukin-6 production Effects 0.000 claims description 4
• 238000012286 ELISA Assay Methods 0.000 claims 1
• 230000003389 potentiating effect Effects 0.000 claims 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 173
• 235000001014 amino acid Nutrition 0.000 description 150
• 125000003275 alpha amino acid group Chemical group 0.000 description 146
• 210000004027 cell Anatomy 0.000 description 136
• 241000282414 Homo sapiens Species 0.000 description 112
• 230000027455 binding Effects 0.000 description 107
• 229940024606 amino acid Drugs 0.000 description 104
• 241000282567 Macaca fascicularis Species 0.000 description 85
• 108090000623 proteins and genes Proteins 0.000 description 71
• 238000000034 method Methods 0.000 description 66
• 150000007523 nucleic acids Chemical group 0.000 description 61
• 239000002158 endotoxin Substances 0.000 description 57
• 229920006008 lipopolysaccharide Polymers 0.000 description 57
• 102000004169 proteins and genes Human genes 0.000 description 56
• 235000018102 proteins Nutrition 0.000 description 53
• 108091028043 Nucleic acid sequence Proteins 0.000 description 50
• 108091007433 antigens Proteins 0.000 description 41
• 102000036639 antigens Human genes 0.000 description 41
• 239000000203 mixture Substances 0.000 description 41
• 239000000427 antigen Substances 0.000 description 39
• 108060003951 Immunoglobulin Proteins 0.000 description 37
• 102000018358 immunoglobulin Human genes 0.000 description 37
• 108090000765 processed proteins & peptides Proteins 0.000 description 32
• 102000005962 receptors Human genes 0.000 description 30
• 101001018020 Homo sapiens Lymphocyte antigen 96 Proteins 0.000 description 29
• 102000045711 human LY96 Human genes 0.000 description 29
• 108020003175 receptors Proteins 0.000 description 29
• 239000013598 vector Substances 0.000 description 27
• 239000012634 fragment Substances 0.000 description 26
• 102000004196 processed proteins & peptides Human genes 0.000 description 26
• 239000013589 supplement Substances 0.000 description 25
• 229920001184 polypeptide Polymers 0.000 description 24
• 230000004913 activation Effects 0.000 description 21
• 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 20
• 230000002209 hydrophobic effect Effects 0.000 description 20
• 150000001875 compounds Chemical class 0.000 description 19
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
• 239000002953 phosphate buffered saline Substances 0.000 description 18
• 230000000770 proinflammatory effect Effects 0.000 description 18
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
• 230000005764 inhibitory process Effects 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 16
• -1 e.g. Substances 0.000 description 16
• 210000004408 hybridoma Anatomy 0.000 description 16
• 239000003795 chemical substances by application Substances 0.000 description 15
• 238000009472 formulation Methods 0.000 description 15
• 229910052727 yttrium Inorganic materials 0.000 description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
• 230000000694 effects Effects 0.000 description 13
• 238000004519 manufacturing process Methods 0.000 description 13
• 235000008729 phenylalanine Nutrition 0.000 description 13
• 241000894007 species Species 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 102000002689 Toll-like receptor Human genes 0.000 description 12
• 108020000411 Toll-like receptor Proteins 0.000 description 12
• 230000016396 cytokine production Effects 0.000 description 12
• 230000014509 gene expression Effects 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 11
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 239000013604 expression vector Substances 0.000 description 11
• 229910052731 fluorine Inorganic materials 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 102000040430 polynucleotide Human genes 0.000 description 11
• 108091033319 polynucleotide Proteins 0.000 description 11
• 239000002157 polynucleotide Substances 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• 238000001514 detection method Methods 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 230000001900 immune effect Effects 0.000 description 10
• 239000002502 liposome Substances 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 230000007170 pathology Effects 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 230000011664 signaling Effects 0.000 description 9
• 230000035882 stress Effects 0.000 description 9
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
• 235000005772 leucine Nutrition 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 239000002245 particle Substances 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 7
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 239000004472 Lysine Substances 0.000 description 7
• 238000010521 absorption reaction Methods 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 229940098773 bovine serum albumin Drugs 0.000 description 7
• 230000002860 competitive effect Effects 0.000 description 7
• 239000002299 complementary DNA Substances 0.000 description 7
• 238000005859 coupling reaction Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 230000004068 intracellular signaling Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 6
• 108091035707 Consensus sequence Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
• 239000004473 Threonine Substances 0.000 description 6
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 235000004279 alanine Nutrition 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 230000008878 coupling Effects 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• 229940127089 cytotoxic agent Drugs 0.000 description 6
• 230000007783 downstream signaling Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 235000011187 glycerol Nutrition 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 229960000310 isoleucine Drugs 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 230000000813 microbial effect Effects 0.000 description 6
• 201000000050 myeloid neoplasm Diseases 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 238000010561 standard procedure Methods 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 239000004474 valine Substances 0.000 description 6
• 235000014393 valine Nutrition 0.000 description 6
• 239000013603 viral vector Substances 0.000 description 6
• 238000013389 whole blood assay Methods 0.000 description 6
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• 108010087819 Fc receptors Proteins 0.000 description 5
• 102000009109 Fc receptors Human genes 0.000 description 5
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 229920002684 Sepharose Polymers 0.000 description 5
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
• 239000012491 analyte Substances 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 235000009582 asparagine Nutrition 0.000 description 5
• 229960001230 asparagine Drugs 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000004637 cellular stress Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 231100000599 cytotoxic agent Toxicity 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 238000010494 dissociation reaction Methods 0.000 description 5
• 230000005593 dissociations Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 229960002989 glutamic acid Drugs 0.000 description 5
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 235000014705 isoleucine Nutrition 0.000 description 5
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 239000012096 transfection reagent Substances 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 description 4
• 208000037976 chronic inflammation Diseases 0.000 description 4
• 230000006020 chronic inflammation Effects 0.000 description 4
• 239000007822 coupling agent Substances 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 4
• 229940099552 hyaluronan Drugs 0.000 description 4
• 229920002674 hyaluronan Polymers 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 239000003094 microcapsule Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 235000020183 skimmed milk Nutrition 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000012384 transportation and delivery Methods 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 208000006820 Arthralgia Diseases 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 241000702421 Dependoparvovirus Species 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
• JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010090804 Streptavidin Proteins 0.000 description 3
• 239000007994 TES buffer Substances 0.000 description 3
• 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 229940009098 aspartate Drugs 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 239000002738 chelating agent Substances 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 239000005038 ethylene vinyl acetate Substances 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 229930195712 glutamate Natural products 0.000 description 3
• 229940049906 glutamate Drugs 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 229940124452 immunizing agent Drugs 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 238000001114 immunoprecipitation Methods 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000004901 leucine-rich repeat Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 235000006109 methionine Nutrition 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
• GICIECWTEWJCRE-UHFFFAOYSA-N 3,4,4,7-tetramethyl-2,3-dihydro-1h-naphthalene Chemical compound CC1=CC=C2C(C)(C)C(C)CCC2=C1 GICIECWTEWJCRE-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
• 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 239000012099 Alexa Fluor family Substances 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 206010027654 Allergic conditions Diseases 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 101710125298 Beta-defensin 2 Proteins 0.000 description 2
• 102100038326 Beta-defensin 4A Human genes 0.000 description 2
• 101710176951 Beta-defensin 4A Proteins 0.000 description 2
• 102000004954 Biglycan Human genes 0.000 description 2
• 108090001138 Biglycan Proteins 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
• 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 208000004852 Lung Injury Diseases 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 108091061960 Naked DNA Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 102100032442 Protein S100-A8 Human genes 0.000 description 2
• 102100032420 Protein S100-A9 Human genes 0.000 description 2
• 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 2
• 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 102000007000 Tenascin Human genes 0.000 description 2
• 108010008125 Tenascin Proteins 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102100030859 Tissue factor Human genes 0.000 description 2
• 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
• 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
• 102100023132 Transcription factor Jun Human genes 0.000 description 2
• 206010069363 Traumatic lung injury Diseases 0.000 description 2
• 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 201000009961 allergic asthma Diseases 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 125000005442 diisocyanate group Chemical group 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000009510 drug design Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000012149 elution buffer Substances 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 238000006911 enzymatic reaction Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004754 hybrid cell Anatomy 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229960002591 hydroxyproline Drugs 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000002637 immunotoxin Effects 0.000 description 2
• 239000002596 immunotoxin Substances 0.000 description 2
• 229940051026 immunotoxin Drugs 0.000 description 2
• 231100000608 immunotoxin Toxicity 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000021995 interleukin-8 production Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 231100000515 lung injury Toxicity 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 239000013586 microbial product Substances 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 229910052759 nickel Inorganic materials 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 229940126701 oral medication Drugs 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 235000013930 proline Nutrition 0.000 description 2
• 229960000856 protein c Drugs 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 238000013391 scatchard analysis Methods 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 239000004017 serum-free culture medium Substances 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• 230000005030 transcription termination Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 238000009423 ventilation Methods 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
• BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
• VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
• YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
• ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
• GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
• PQYGLZAKNWQTCV-HNNXBMFYSA-N 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA Chemical compound OCCNC(=S)NC1=CC=C(C[C@@H](CN(CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 PQYGLZAKNWQTCV-HNNXBMFYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• CQXXYOLFJXSRMT-UHFFFAOYSA-N 5-diazocyclohexa-1,3-diene Chemical class [N-]=[N+]=C1CC=CC=C1 CQXXYOLFJXSRMT-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 241001316595 Acris Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 239000012114 Alexa Fluor 647 Substances 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 241000700663 Avipoxvirus Species 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800001415 Bri23 peptide Proteins 0.000 description 1
• 101800000655 C-terminal peptide Proteins 0.000 description 1
• 102400000107 C-terminal peptide Human genes 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010060123 Conjugate Vaccines Proteins 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 108700020359 Drosophila Tl Proteins 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 101710082714 Exotoxin A Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 102000000849 HMGB Proteins Human genes 0.000 description 1
• 108010001860 HMGB Proteins Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
• 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 101150067401 Ly96 gene Proteins 0.000 description 1
• 102100033446 Lymphocyte antigen 96 Human genes 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
• PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
• 101800000597 N-terminal peptide Proteins 0.000 description 1
• 102400000108 N-terminal peptide Human genes 0.000 description 1
• WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000037656 Respiratory Sounds Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 102400000827 Saposin-D Human genes 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007984 Tris EDTA buffer Substances 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 206010047924 Wheezing Diseases 0.000 description 1
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
• 206010060926 abdominal symptom Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical class C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000012805 animal sample Substances 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000002032 cellular defenses Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 208000004209 confusion Diseases 0.000 description 1
• 229940031670 conjugate vaccine Drugs 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000009402 cross-breeding Methods 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 206010013395 disorientation Diseases 0.000 description 1
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 150000002222 fluorine compounds Chemical class 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 239000000852 hydrogen donor Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
• 229940097277 hygromycin b Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 230000002687 intercalation Effects 0.000 description 1
• 238000009830 intercalation Methods 0.000 description 1
• 108090000237 interleukin-24 Proteins 0.000 description 1
• 102000003898 interleukin-24 Human genes 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000011325 microbead Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 238000007480 sanger sequencing Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1